Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.
Data(s) |
01/09/2014
|
---|---|
Resumo |
Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) are well established in treating metastatic pulmonary adenocarcinoma, especially patients with activating EGFR mutations. EGFR mutations are rare in pulmonary squamous cell carcinomas (SCCs). There are conflicting data supporting the efficacy of EGFR-TKIs in advanced lung SCC. We analyzed the impact of EGFR-TKIs on progression-free survival (PFS) and overall survival (OS) in unselected patients with lung SCC. |
Identificador | |
Idioma(s) |
eng |
Publicador |
Wiley-Blackwell |
Relação |
http://dro.deakin.edu.au/eserv/DU:30069608/khasraw-epidermalgrowth-2014.pdf http://www.dx.doi.org/10.1111/ajco.12231 http://www.ncbi.nlm.nih.gov/pubmed/25135201 |
Direitos |
2014, Wiley-Blackwell |
Palavras-Chave | #epidermal growth factor (EGFR) inhibitor #lung cancer #meta-analysis #squamous cell carcinoma #tyrosine kinase inhibitor (TKI) #Science & Technology #Life Sciences & Biomedicine #Oncology #ERLOTINIB MAINTENANCE THERAPY #RANDOMIZED PHASE-II #DOUBLE-BLIND #2ND-LINE TREATMENT #EGFR MUTATIONS #OPEN-LABEL #CANCER #PLACEBO #GEFITINIB #CHEMOTHERAPY |
Tipo |
Journal Article |